Endocrinology

Your daily dose of clinical news you may have missed.

Listen to 2 obesity experts discuss the impact of the COVID-19 pandemic on obesity-related type 2 diabetes.

Retatrutide, survodutide, orforglipron. The 3 new GLP-1 agonist-based AOMs showed weight loss of up to 20% and are well worth watching.

Your daily dose of clinical news you may have missed.

ADA 2023: The only nonstatin therapy to reduce risk for 4-point MACE in ASCVD may potentially find a role in primary prevention as well, though caution is advised.

ADA 2023. Results from PIONEER PLUS trial showed oral semaglutide 25 mg and 50 mg were superior than 14 mg in reducing HbA1c and body weight in adults with T2D.

ADA 2023: Weight loss with the combination GLP-1/GIP/glucagon receptor agonist was as high as 30% in study participants who received the highest dose.

Your daily dose of clinical news you may have missed.

ADA 2023. Once-daily oral semaglutide 50 mg induced 15.1% weight loss in adults with overweight or obesity without type 2 diabetes vs placebo.

Your daily dose of clinical news you may have missed.

ADA 2023: The investigational oral GLP-1 RA resulted in weight loss comparable to injectable GLP-1 RA formulations and requires no food or water restrictions.

ADA 2023: SURMOUNT-2 findings show tirzepatide is associated with greater weight loss in adults with T2D than any other treatment studied to date.

Type 2 diabetes will continue to comprise more than 90% of this population and obesity will be the primary driver, according to Global Burden of Disease researchers.

ADA 2023. Retatrutide, an investigational triple GLP-1/GIP/glucagon agonist, may provide benefits in liver fibrosis and obesity as well as in glycemic control.

SGLT-2 inhibitors were found to consistently reduce risk of CV mortality and HF events in a meta-analysis including 90 000 high-risk patients with T2D, CKD, and/or HF.

Early intervention is important to reduce the risk for complications for patients with obesity and type 2 diabetes. Two obesity experts explain more, here.

The 2 SGLT-2 inhibitor-based medications are the first in the class to be approved for pediatric T2D and provide a much needed additional oral treatment option for the population.

Your daily dose of clinical news you may have missed.

ENDO 2023. In older men with hypogonadism and CVD, there was no difference in incident CVD between those taking testosterone and those taking placebo.

ENDO 2023. Women with PCOS face an increased risk of mortality, particularly death due to cardiovascular disease and diabetes, compared with those without PCOS.

Your daily dose of clinical news you may have missed.

Eden Miller, DO, shares key takeaways on how personalized treatment helps in the management of diabetes.

Elizabeth Holt, MD, FACE, and Eden Miller, DO, comment on the pros and cons of real-world data studies, looking particularly at the study of the OneTouch Verio Flex meter and the OneTouch Reveal apps.

Experts discuss steps to introduce the OneTouch Verio Flex meter and the OneTouch Reveal app to patients to better manage diabetes.

ENDO 2023. The pattern of intermittent fasting improved glycemic measures in a weight-independent fashion after just 7 days, according to the study abstract.

Finerenone was associated with a decrease in composite CV risk in patients with CKD, T2D, eGFR of ≥25, and moderately to severely increased albuminuria.

Nearly half of responding medical professionals said patients without T2D have asked for an Ozempic Rx and about 18% of them have provided one, avoiding significant backlash for a denial.

Your daily dose of clinical news you may have missed.

Patients with diabetes had a 35% higher risk of COPD compared with those without diabetes, according to new research.

Try this 7-question quiz on the 2023 guidelines from The Endocrine Society that focus on advances in diabetes treatment that help minimize risk of hypoglycemia.